Clinical Trial Update: Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032) [Phase 1]

View source ↗

Summary

Phase 1 study in Chinese participants with non-small cell lung cancer evaluating safety, tolerability, pharmacokinetics, and efficacy of pembrolizumab (MK-3475)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-Small-Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2019-10-07